HROW Harrow Health, Inc.
USHealthcareAs of 2026-07-10 16:00
Why HROW matters now
Harrow Health, Inc. (HROW) is a US stock in Healthcare. The latest InvestLog snapshot shows $42.48 with -1.05% on the session and $1.58B in market capitalization; recent performance reads 1-month +39.73% and YTD -12.51%.
The latest financial table shown here is Q1 2026, with revenue of $44.2M, net income of $-27.6M, and EPS of $-0.74. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.9%.
The latest indexable market news headline is "Harrow Announces Commercial Launch of BYOOVIZ® in the United States" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $70.00; recent insider activity includes SILVERNAIL LAUREN P filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
55.60
P/S
5.95
EV/EBITDA
57.33
DCF Value
$-495.96
FCF Yield
0.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
74.1%
Operating Margin
10.5%
Net Margin
-5.6%
ROE
-33.7%
ROA
-3.6%
ROIC
8.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $44.2M | $-27.6M | $-0.74 |
| Q4 2025 | $89.1M | $6.6M | $0.18 |
| FY 2025 | $272.3M | $-5.1M | $-0.14 |
| Q3 2025 | $71.6M | $1.0M | $0.03 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$73.67
Target (Median)
$70.00
Target Range
$63.00 - $88.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.28
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.